DRUG BRIGHT MINDS BIOSCIENCES INC. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1827401 · Reporting currency CAD · Fiscal year ends 09/30
Financial factors as of 2024-09-30 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | 2019Q4*2019-09-30 |
|---|---|
| Income statement | |
| Revenue | — |
| R&D expense | 42,009 |
| SG&A expense | 0 |
| Net income | -78,717 |
| EPS (basic) | -0.04 |
| EPS (diluted) | -0.04 |
| Balance sheet | |
| Cash & equivalents | 79,991 |
| Total assets | — |
| Shareholders' equity | 45,283 |
| Cash flow statement | |
| Operating cash flow | -42,009 |
| Financing cash flow | 122,000 |
| Stock-based compensation | 0 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.